Literature DB >> 25288442

An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record database.

S Unni1, Y Yao, N Milne, K Gunning, J R Curtis, J LaFleur.   

Abstract

SUMMARY: Many of the clinical risk factors used in fracture risk assessment (FRAX) calculator are available in electronic medical record (EMR) databases and are good sources of osteoporosis risk factor information. The EPIC EMR database showed a lower prevalence of FRAX risk factors and, consequently, proportion of patients who would be deemed "high risk."
INTRODUCTION: The FRAX tool is underutilized for osteoporosis screening. Many of the clinical risk factors for FRAX may be available in EMR databases and may enable health systems to perform fracture risk assessments. We intended to identify variables in an EMR database for calculating FRAX score in a cohort of postmenopausal women, to estimate absolute fracture risk, and to determine the proportions of women whose absolute fracture risks exceed the National Osteoporosis Foundation (NOF) thresholds.
METHODS: Our cohort was selected using an EMR database with demographic, inpatient, outpatient, and clinical information for female patients age≥50 in a family practice, internal medicine, or obstetrics/gynecology clinic in 2007-2008. The latest physician encounter was the index date. Variables, problem and medication lists, diagnosis codes, and histories from the EMR were used to populate the 11 clinical risk factor variables used in the FRAX. These risk factor prevalence and treatment-eligible proportions were compared to those of published epidemiology studies.
RESULTS: The study included 345 patients. Mean (SD) 10-year risk for any major fracture was 11.1% (6.8) when bone mineral density (BMD) was used and 11.2% (6.5) when BMI was used. About 10.1% of the cohort exceeded the NOF's 20% major fracture risk threshold and 32.5% exceeded the NOF's 3% hip fracture risk threshold when BMD was used. Overall, the number of treatment-eligible patients was slightly lower when FRAX was calculated using BMD versus BMI (13.6 and 36.8%).
CONCLUSION: Our cohort using EMR data most likely underestimated the mean 10-year probability of any major fracture compared to other cohorts in published literature. The difference may be in the nature of EMRs for supporting only passive data collection of risk factor information.

Entities:  

Mesh:

Year:  2014        PMID: 25288442     DOI: 10.1007/s00198-014-2899-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  22 in total

Review 1.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

Review 2.  Managing osteoporosis: challenges and strategies.

Authors:  E Michael Lewiecki
Journal:  Cleve Clin J Med       Date:  2009-08       Impact factor: 2.321

3.  Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort.

Authors:  M E Arlot; E Sornay-Rendu; P Garnero; B Vey-Marty; P D Delmas
Journal:  J Bone Miner Res       Date:  1997-04       Impact factor: 6.741

4.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

Review 5.  Body mass index as a predictor of fracture risk: a meta-analysis.

Authors:  C De Laet; J A Kanis; A Odén; H Johanson; O Johnell; P Delmas; J A Eisman; H Kroger; S Fujiwara; P Garnero; E V McCloskey; D Mellstrom; L J Melton; P J Meunier; H A P Pols; J Reeve; A Silman; A Tenenhouse
Journal:  Osteoporos Int       Date:  2005-06-01       Impact factor: 4.507

6.  Fracture risk tool validation in an integrated healthcare delivery system.

Authors:  Joan C Lo; Alice R Pressman; Malini Chandra; Bruce Ettinger
Journal:  Am J Manag Care       Date:  2011-03       Impact factor: 2.229

7.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24

9.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks.

Authors:  N D Nguyen; S A Frost; J R Center; J A Eisman; T V Nguyen
Journal:  Osteoporos Int       Date:  2008-03-07       Impact factor: 4.507

10.  Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.

Authors:  Jeffrey R Curtis; Leslie A McClure; Elizabeth Delzell; Virginia J Howard; Eric Orwoll; Kenneth G Saag; Monika Safford; George Howard
Journal:  J Gen Intern Med       Date:  2009-06-24       Impact factor: 5.128

View more
  3 in total

1.  Summary perioperative risk metrics within the electronic medical record predict patient-level cost variation in pancreaticoduodenectomy.

Authors:  Christopher C Stahl; Patrick B Schwartz; Glen E Leverson; James R Barrett; Taylor Aiken; Alexandra W Acher; Sean M Ronnekleiv-Kelly; Rebecca M Minter; Sharon M Weber; Daniel E Abbott
Journal:  Surgery       Date:  2020-04-26       Impact factor: 3.982

2.  Use of an electronic medical record dashboard to identify gaps in osteoporosis care.

Authors:  A Papaioannou; E McCloskey; A Bell; D Ngui; U Mehan; M Tan; L Goldin; A Langer
Journal:  Arch Osteoporos       Date:  2021-04-24       Impact factor: 2.617

Review 3.  Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis.

Authors:  Lihua Peng; Qian Luo; Hui Lu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.